Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Japan
/
Pharmaceuticals & Biotech
/
PeptiDream
4587
PeptiDream
Licensing Delays Will Downturn Revenues But Enable Future Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
31 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
JP¥2,500.00
34.8% undervalued
intrinsic discount
16 Aug
JP¥1,629.50
Loading
1Y
-27.2%
7D
2.2%
Author's Valuation
JP¥2.5k
34.8% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
JP¥2.5k
34.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-5b
55b
2014
2017
2020
2023
2025
2026
2028
Revenue JP¥47.5b
Earnings JP¥11.9b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
18.44%
Biotech revenue growth rate
13.35%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.72%
Calculation
JP¥11.87b
Earnings '28
x
30.96x
PE Ratio '28
=
JP¥367.48b
Market Cap '28
JP¥367.48b
Market Cap '28
/
128.03m
No. shares '28
=
JP¥2.87k
Share Price '28
JP¥2.87k
Share Price '28
Discounted to 2025 @ 4.72% p.a.
=
JP¥2.50k
Fair Value '25
